Purple Biotech (NASDAQ/TASE: PPBT) announced it will present a poster at the European Association for Cancer Research (EACR) 2025 Congress in Lisbon, Portugal from June 16-19, 2025. The presentation will focus on their CAPTN-3 tri-specific antibody platform, a novel technology for conditionally activated T cell and NK cell engagers. Dr. Hadas Reuveni, VP of R&D at Purple Biotech, will present the poster titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers" during the Immunotherapy session on June 17, 2025. The abstract (EACR25-1964) will be published online after the presentation.
Purple Biotech (NASDAQ/TASE: PPBT) ha annunciato che presenterà un poster al Congresso 2025 della European Association for Cancer Research (EACR), che si terrà a Lisbona, Portogallo, dal 16 al 19 giugno 2025. La presentazione sarà incentrata sulla loro piattaforma di anticorpi tri-specifici CAPTN-3, una tecnologia innovativa per l'attivazione condizionale degli engager delle cellule T e delle cellule NK. La Dott.ssa Hadas Reuveni, VP di R&S presso Purple Biotech, presenterà il poster intitolato "CAPTN-3: una nuova piattaforma di engager condizionatamente attivati per cellule T e NK" durante la sessione di Immunoterapia il 17 giugno 2025. L'abstract (EACR25-1964) sarà pubblicato online dopo la presentazione.
Purple Biotech (NASDAQ/TASE: PPBT) anunció que presentará un póster en el Congreso 2025 de la Asociación Europea para la Investigación del Cáncer (EACR), que se celebrará en Lisboa, Portugal, del 16 al 19 de junio de 2025. La presentación se centrará en su plataforma de anticuerpos trispecíficos CAPTN-3, una tecnología novedosa para activadores condicionales de células T y células NK. La Dra. Hadas Reuveni, vicepresidenta de I+D en Purple Biotech, presentará el póster titulado "CAPTN-3: Una nueva plataforma de activadores condicionales de células T y NK" durante la sesión de Inmunoterapia el 17 de junio de 2025. El resumen (EACR25-1964) se publicará en línea después de la presentación.
Purple Biotech(NASDAQ/TASE: PPBT)는 2025년 6월 16일부터 19일까지 포르투갈 리스본에서 열리는 유럽암연구협회(EACR) 2025년 총회에서 포스터를 발표할 예정이라고 발표했습니다. 이번 발표는 조건부 활성화된 T세포 및 NK세포 엔게이저를 위한 혁신적인 기술인 CAPTN-3 삼중특이성 항체 플랫폼에 초점을 맞출 것입니다. Purple Biotech 연구개발 부사장인 하다스 루에베니 박사가 2025년 6월 17일 면역치료 세션에서 "CAPTN-3: 조건부 활성화된 T세포 및 NK세포 엔게이저를 위한 새로운 플랫폼"이라는 제목의 포스터를 발표할 예정입니다. 초록(EACR25-1964)은 발표 후 온라인에 게시될 예정입니다.
Purple Biotech (NASDAQ/TASE : PPBT) a annoncé qu'elle présentera un poster lors du Congrès 2025 de l'Association Européenne pour la Recherche sur le Cancer (EACR) qui se tiendra à Lisbonne, Portugal, du 16 au 19 juin 2025. La présentation portera sur leur plateforme d'anticorps tri-spécifiques CAPTN-3, une technologie innovante pour l'activation conditionnelle des engageurs de cellules T et NK. Le Dr Hadas Reuveni, vice-présidente R&D chez Purple Biotech, présentera le poster intitulé « CAPTN-3 : Une nouvelle plateforme d'engageurs conditionnellement activés des cellules T et NK » lors de la session Immunothérapie le 17 juin 2025. Le résumé (EACR25-1964) sera publié en ligne après la présentation.
Purple Biotech (NASDAQ/TASE: PPBT) gab bekannt, dass es auf dem Kongress der European Association for Cancer Research (EACR) 2025, der vom 16. bis 19. Juni 2025 in Lissabon, Portugal, stattfindet, ein Poster präsentieren wird. Die Präsentation konzentriert sich auf ihre CAPTN-3 trispezifische Antikörper-Plattform, eine neuartige Technologie für bedingt aktivierte T-Zell- und NK-Zell-Engager. Dr. Hadas Reuveni, VP für Forschung und Entwicklung bei Purple Biotech, wird das Poster mit dem Titel „CAPTN-3: Eine neuartige Plattform für bedingt aktivierte T-Zell- und NK-Zell-Engager“ während der Immunotherapie-Sitzung am 17. Juni 2025 vorstellen. Das Abstract (EACR25-1964) wird nach der Präsentation online veröffentlicht.
Positive
None.
Negative
None.
REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025.
EACR poster details are as follows:
Abstract #: EACR25-1964 Title: “CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers” Session Title: Immunotherapy Session Date and Time: June 17, 2025, from 10:45 to 20:00 Presenting Author: Dr. Hadas Reuveni, Vice President of R&D, Purple Biotech
Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website.
About Purple Biotech Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The Company is advancing NT219 into a Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients in combination with cetuximab or pembrolizumab. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
